Description
Cagrilintide powder is a long-acting human amylin analogue optimized through esterification and sequence engineering, belonging to the amylin-calcitonin receptor family of agonists. Its key feature is that weekly dosing maintains its active signal, making it suitable for mechanistic and pharmacodynamic studies focusing on satiety pathways, gastric exhaustion regulation, and glucagon regulation.
The Cagrilintide provided by Shaanxi Medibridge is a research-grade (RUO) lyophilized powder. Quality control covers key indicators such as identification, purity, impurities and residues, salt form, and content. Low endotoxin/dedicated buffer systems and customized label versions are available to meet the needs of cellular and animal pharmacodynamic experiments.
COA
|
Item |
Standard |
Results |
|
Purity |
≥98% |
99.85% |
|
Peptide Assay |
≥80% |
92.66% |
|
Mass Spectrum |
4409 |
4409 |
|
Solubility |
Soluble in water |
Complies |
|
Clarity and color of solution |
Clear and colorless |
Complies |
|
Sodium salt |
<5.0% |
1.33% |
|
Water |
≤7.0% |
2.58% |
|
Residual Solvent: Methanol |
||
|
≤0.3% |
0.0054% |
|
|
Isopropanol |
≤0.5% |
N.D. |
|
Acetonitrile |
≤0.041% |
0.039% |
|
Methylene Chloride |
≤0.06% |
0.019% |
|
N,N-Dimethylformamide |
≤0.088% |
0.051% |
|
Triethylamine |
≤0.032% |
N.D. |
|
Tert-butyl methyl ether |
≤0.5% |
0.232% |
|
Endotoxin |
≤0.5 EU/mg |
Complies |
|
Microbial Limit |
Total aerobic bacteria <100 CFU/g Total yeast & mold <50 CFU/g |
<50 CFU/g <10 CFU/g |
|
Storage |
Keep in dark and cool dry place (-20 to 8°C) |
|
|
Conclusion |
The batch conforms to the IN-HOUSE standard |
|
Specifications (for research use only)
|
Form |
Sample Order |
Specification |
|
Raw powder |
1 g |
Purity is NLT 99.85% |
|
Vials |
10 vials |
3ml/5ml/7ml/15ml vials etc. |
Research Direction(For academic exchange only, with no clinical use.)
Suitable Research Directions for Cagrilintide
The research focuses on the subtype differences of the CTR+RAMP1/2/3 complex. cAMP, β-arrestin, and ERK time curves can be performed in stably expressing HEK293/CHO cell lines to compare Emax/EC50 and kinetic (on/off-rate) differences, assessing the presence of biased agonism.
Focusing on the linkage between ligand binding and receptor endocytosis: BRET/NanoBiT or TR-FRET binding kinetics combined with confocal internalization trajectories can help explain effect persistence and desensitization.
Key technical points: Low-adsorption consumables; 0.1% BSA or equivalent carriers to reduce peptide adsorption; aliquoting and cryopreservation to avoid freeze-thaw cycles; control groups should include both family peptides and inactivated mutant peptides to facilitate differentiation of receptor-specific effects.
GI Motility & Postprandial Hormones
In animal models, gastric emptying can be assessed using the acetaminophen (APAP) method. Combined with postprandial blood glucose, glucagon, and insulin curves, an evidence chain of "delayed gastric emptying-reduced postprandial blood glucose fluctuations" can be established.
In vitro, the indirect effects of intestinal hormone (GLP-1, PYY) release can be observed using intestinal fragments or organoids to verify the existence of gut-brain feedback enhancement.
Note that strong alkaline/high organic solvent systems can affect peptide stability; kinetic experiments are recommended to be conducted in a buffer system with a pH of 4.5–6.5.
Obesity models & Pharmacodynamics
DIO mice/rats are the basic model: Cagrilintide powder administration is repeated for several weeks, monitoring body weight, body fat mass (EchoMRI/DXA), and meal pattern, and energy expenditure and respiratory quotient (RER) are assessed using metabolic cages.
Using a paired feeding control can separate the contributions of "suppressed feeding" and "increased energy expenditure"; combining this with OGTT/ITT or hyperinsulin-euglycemic clamps enhances the persuasiveness of glucose metabolism conclusions.
It is recommended to add behavioral tolerance indicators (such as mouse lithotripsy/kaolin ingestion and conditioned taste aversion) to differentiate between pharmacological anorexia and adverse reactions.
Combination therapy &Synergy
Combination therapy with GLP-1/GIP/GLP-1+GIP peptides, SGLT2 inhibitors, or glucagon receptor modulators can produce complementary effects across different dimensions, including food intake control, postprandial blood glucose, and lipid metabolism.
Designing dose matrices and equivalent coordinate systems (Bliss/Loewe/HSA) to assess synergistic properties; controlling titration rates and recording the onset and relief times of gastrointestinal discomfort to balance efficacy and tolerability.
Key analytical points: Whether the plateau phase is delayed, whether rebound is reduced, and weight maintenance after discontinuation of medication.
Hepatic lipid metabolism & NAFLD/NASH
In WD+fructose or MCD models, we observed hepatic lipid deposition and inflammatory fibrosis markers (liver TG, H&E/Oil Red O, NAS score, Sirius Red), combined with transcriptomics/lipomics analysis to elucidate pathway changes.
Simultaneously, we monitored blood lipids (TG, VLDL, non-esterified fatty acids) and inflammatory markers (CRP/cytokines) to construct a causal chain of "weight loss-lipid metabolism remodeling-increased inflammation."
Including hepatic insulin sensitivity (glucose production inhibition) as an endpoint helps distinguish between simple weight loss effects and liver-specific effects.
FAQ
Q: What are some safer procedures if dissolution is unsuccessful?
A: Let the lyophilized powder warm to room temperature for 5–10 minutes, avoiding direct contact between condensate and the powder.
Dissolve with a small amount of acidified water (e.g., 2 mM HCl or 0.1% glacial acetic acid, the volume should be just enough to wet the powder).
Q: Recommended solvent and pH range?
A: It is recommended for long-term storage and use in a buffer system with a pH of 4.5–6.5 (e.g., acetate/citrate system). Avoid strong alkaline environments (pH > 8), strong oxidizing agents, and environments with a high proportion of organic solvents.
Q: Storage and aliquoting recommendations after reconstitution?
A: Cagrilintide powder: Store in a cool, dry place away from light at -20 to -80°C; batch stability is typically 18–24 months (based on COA). Minimize freeze-thaw cycles (no more than 2 times recommended). Immediately after the first reconstitution, aliquot the powder into equal portions for testing.
Q: Transportation, receiving, and appearance?
A: Slight shrinkage or adhesion of the freeze-dried blocks is normal and does not affect quality. Please contact us immediately if you observe abnormal deliquescence or container damage.
Q: Can this be used directly in animals/clinically?
A: This product is for research use only (RUO) and must not be used for human or veterinary diagnosis, treatment, or direct administration.
Q: Do you have production and quality management qualifications?
A: We have a complete peptide R&D and production platform. Our quality system is managed and recorded according to GMP principles. We can provide complete COA/SDS and batch traceability; we also support customized services such as labeling and low endotoxin levels.
Applying Cagrilintide to obesity treatment is a novel and promising path for improving glycemic management. If you need a high‑purity peptide partner for enduring cooperation, email hi@medibridgeapi.com. Or message us on WhatsApp at +44 07548632075.
Hot Tags: cagrilintide powder, China cagrilintide powder manufacturers, suppliers, factory, BPC 157 Powder, Survodutide Peptide, Ghrp Peptide, Selank Powder, Peptide SS 31, Thymosin Alpha 1 Peptide
